J M FitzGerald1, A Becker, M R Sears, S Mink, K Chung, J Lee. 1. Respiratory Medicine, Center for Clinical Epidemiology and Evaluation, University of British Columbia, Vancouver General Hospital Research Pavilion, 822 West 10th Avenue, Vancouver, BC, Canada V5Z 1L8. markf@interchange.ubc.ca
Abstract
BACKGROUND: Previous guidelines recommend doubling the daily dose of maintenance inhaled corticosteroid to treat or prevent progression of exacerbations of asthma. METHODS: Over a 6 month period a cohort of patients were evaluated prospectively and randomised in a double blind controlled trial to treatment with either a continued maintenance dose (MD) of inhaled corticosteroid or doubling the dose (DD) at the time of an exacerbation. RESULTS: A total of 290 patients were randomised (33% male) and 98 (DD, n = 46) experienced evaluable asthma exacerbations during the study period. Mean (SD) baseline characteristics at randomisation (age 33.5 (14.0) years; forced expiratory volume in 1 second (FEV(1)) 2.8 (0.7) l; peak expiratory flow (PEF) 422.9 (110.5) l/min) were similar in both groups. In the DD group 41% of patients were considered treatment failures because they either required systemic steroids (n = 12), had an unscheduled visit to a physician (n = 1), or their asthma did not return to baseline (n = 6). This did not differ from the MD group in which 40% were treatment failures (n = 9, 0, and 12, respectively; p = 0.94). CONCLUSIONS: In patients who regularly take an inhaled corticosteroid, doubling the maintenance dose may not affect the pattern of the exacerbation.
RCT Entities:
BACKGROUND: Previous guidelines recommend doubling the daily dose of maintenance inhaled corticosteroid to treat or prevent progression of exacerbations of asthma. METHODS: Over a 6 month period a cohort of patients were evaluated prospectively and randomised in a double blind controlled trial to treatment with either a continued maintenance dose (MD) of inhaled corticosteroid or doubling the dose (DD) at the time of an exacerbation. RESULTS: A total of 290 patients were randomised (33% male) and 98 (DD, n = 46) experienced evaluable asthma exacerbations during the study period. Mean (SD) baseline characteristics at randomisation (age 33.5 (14.0) years; forced expiratory volume in 1 second (FEV(1)) 2.8 (0.7) l; peak expiratory flow (PEF) 422.9 (110.5) l/min) were similar in both groups. In the DD group 41% of patients were considered treatment failures because they either required systemic steroids (n = 12), had an unscheduled visit to a physician (n = 1), or their asthma did not return to baseline (n = 6). This did not differ from the MD group in which 40% were treatment failures (n = 9, 0, and 12, respectively; p = 0.94). CONCLUSIONS: In patients who regularly take an inhaled corticosteroid, doubling the maintenance dose may not affect the pattern of the exacerbation.
Authors: P M O'Byrne; P J Barnes; R Rodriguez-Roisin; E Runnerstrom; T Sandstrom; K Svensson; A Tattersfield Journal: Am J Respir Crit Care Med Date: 2001-10-15 Impact factor: 21.405
Authors: J M FitzGerald; D Shragge; J Haddon; B Jennings; J Lee; T Bai; P Pare; D Kassen; A Grunfeld Journal: Can Respir J Date: 2000 Jan-Feb Impact factor: 2.409
Authors: K Grünberg; R F Sharon; J K Sont; J C In 't Veen; W A Van Schadewijk; E P De Klerk; C R Dick; J H Van Krieken; P J Sterk Journal: Am J Respir Crit Care Med Date: 2001-11-15 Impact factor: 21.405
Authors: Agnieszka Szot; Francine L Jacobson; Samson Munn; Darius Jazayeri; Edward Nardell; David Harrison; Ralph Drosten; Lucila Ohno-Machado; Laura M Smeaton; Hamish S F Fraser Journal: Int J Med Inform Date: 2004-02 Impact factor: 4.046
Authors: M Diane Lougheed; Catherine Lemiere; Francine M Ducharme; Chris Licskai; Sharon D Dell; Brian H Rowe; Mark Fitzgerald; Richard Leigh; Wade Watson; Louis-Philippe Boulet Journal: Can Respir J Date: 2012 Mar-Apr Impact factor: 2.409
Authors: Katherine Rivera-Spoljaric; Vernon M Chinchilli; Lindsay J Camera; Robert S Zeiger; Ian M Paul; Brenda R Phillips; Lynn M Taussig; Robert C Strunk; Leonard B Bacharier Journal: J Pediatr Date: 2009-03-25 Impact factor: 4.406
Authors: T E Albertson; M Schivo; N Gidwani; N J Kenyon; M E Sutter; A L Chan; S Louie Journal: Clin Rev Allergy Immunol Date: 2015-02 Impact factor: 8.667